MS-Komplextreatment Benefit Study

MS-Komplextreatment Benefit Study - MS-KOM. Benefit Study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00032034

Enrollment

200

Registered

2023-06-09

Start date

2023-06-05

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

RRMS, SPMS, PPMS and the benefit of intensive treatment, especially of cognition.

Interventions

Group 1: 200 MS patients or the number of patients who participated in the complex treatment up to 05/31/2025.

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Multiple sclerosis

Exclusion criteria

Exclusion criteria: lack of consent

Design outcomes

Primary

Measure	Time frame
Improvement in cognition, quality of life, depression, fatigue, walking distance, reduction in spasticity after two weeks of complex MS treatment.	—

Countries

Germany

Contacts

Public ContactUlrike von der Osten-Sacken

GZG-Meisenheim

u.osten-sacken@gzg.landeskrankenhaus.de0675391014026

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026